Zhongguancun: 34 in-production products included in the national medical insurance directory.

Zhongguancun announced that some drugs belonging to its wholly-owned subsidiary Si Huan Pharmaceutical's controlling subsidiaries Beijing Huasu, Shandong Huasu, and Duoduo Pharma have been included in the "National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog," with a total of 34 products in production selected, including newly produced and sold products such as Fish Protein Sulfate and Enzyme Compound Powder for Injection. Products previously included in the "Medical Insurance Catalog 2024" such as Bisoprolol Fumarate and Amlodipine Hydrochloride tablets continue to be selected. Beijing Huasu's "Compound Chloropentzine Injection" has been removed from the "Medical Insurance Catalog 2025," while Duoduo Pharma's "Aminophylline Hydrochloride Injection" has been newly included. The sales of the selected products in the future may be affected by various factors such as changes in market conditions, but will not have a significant impact on the company's current operating performance.